Possible Improvement in Survival for Mesothelioma Patients

A very hopeful article was recently released from It described a treatment, multi-pronged treatment, that may improve survival for mesothelioma patients. This hope extends to patients with stage I through III pleural mesothelioma lung cancer.

This recently released article describes a new study from the Journal of Clinical Oncology reports findings that suggest that the survival rate of the above mentioned patient demographis may improve by using a battery of different forms of treatments, including chemotherapy prior to surgery.

About Mesothelioma

Mesothelioma is a rare kind of cancer that is intimately correlated with exposure to asbestos. Many mesothelioma law suits have been fought to demonstrate the link between asbestos and mesothelioma. It is now strongly suggested that exposure to asbestos causes the development of several asbestos-related illnesses; lung cancer, asbestosis and malignant pleural mesothelioma. The problem that many who are afflicted by this are now experiencing is that those exposed do not experience symptoms until at least 10 – 50 years have passed, resulting in a multitude of mesothelioma lawsuits several years after exposure.

Mesothelioma & Multi-Pronged Treatment

The new treatment that is being advocated, multi-pronged treatment, involves several steps to the actual treatment, hence the name for the treatment. Researchers began this treatment by administering chemotherapy before surgery using the medications Alimta and Platinol with the aim of first reducing the size of the cancer. The next step is surgery to remove the diseased lung which is described as the second phase of the multi-pronged approach.

The final phase of this approach involves receiving radiation therapy. This study reported strong statistics supporting the hope that this treatment will improve survival rates among mesothelioma patients.

Those participants in this study that underwent all three phases of the multi-pronged treatment had a two-year survival rate of 61% which is a vast improvement over previous rates. The conclusion of researchers involved in this study is that it produced reasonable long-term survival results.

Learn More...

April 21, 2010

The Invisible Dangers Of Asbestos Fibers

Asbestos at one time was almost a miracle element, everyone loved it. It was in ...

September 15, 2009

Possible Improvement in Survival for Mesothelioma Patients

A very hopeful article was recently released from It desc...

Do I Have A Case?

We offer free consultation. No office visit required, we will get back to you within 24 hours.

  • This field is for validation purposes and should be left unchanged.


What can we do for you?

  • Answer your legal question.
  • Provide a Free Case Evaluation.
  • Schedule an appointment.


Choose Us?

  • Available 24/7
  • Trusted Since 1990
  • Local to You
  • Recovered $350,000,000
  • 5 Star Reviews
  • Free Case Evaluation
  • VIP Service
  • No Win, No Fee

Latest Law Post

October 15, 2019

Zantac Recalled In All Markets

GlaxoSmithKline said on October 8, 2019 that it was recalling their popular heartburn medication Zantac in all markets as a precaution. This comes mere days after the U.S. Food and Drug Administration (FDA) found “unacceptable” levels of the carcinogen NDMA in the medicine.

October 2, 2019

Hidden FDA Database Concealed Reports of Surgical Stapler Malfunctions

A hidden FDA database of medical device failures was shut down in June 2019. The database contains medical device reports submitted to the FDA via its Alternative Summary Reporting Program from 1999 to 2019. Reports which were sent to this database were not, until recently, made public. The Alternative Summary Reporting Program is a non-public database, unlike the FDA’s MAUDE database which publicly logs medical device failures or defects for public review.


We are Personal Injury Lawyers representing accident victims throughout California.
For 30 years, the law firm of Nadrich & Cohen, LLP has helped injury victims
obtain the compensation they deserve.